Neurobiology of Huntington’s Disease

  • Rebecca A. G. De Souza
  • Blair R. Leavitt
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 22)


Of the neurodegenerative diseases presented in this book, Huntington’s disease (HD) stands as the archetypal autosomal dominantly inherited neurodegenerative disorder. Its occurrence through generations of affected families was noted long before the basic genetic underpinnings of hereditary diseases was understood. The early classification of HD as a distinct hereditary neurodegenerative disorder allowed the study of this disease to lead the way in the development of our understanding of the mechanisms of human genetic disorders. Following its clinical and pathologic characterization, the causative genetic mutation in HD was subsequently identified as a trinucleotide (CAG) repeat expansion in the huntingtin (HTT) gene, and consequently, the HTT gene and huntingtin protein have been studied in great detail. Despite this concentrated effort, there is still much about the function of huntingtin that still remains unknown. Presented in this chapter is an overview of the current knowledge on the normal function of huntingtin and some of the potential neurobiologic mechanisms by which the mutant HTT gene may mediate neurodegeneration in HD.


Huntington’s disease Neurodegeneration Huntingtin Disease mechanisms 


  1. Altar CA, Cai N, Bliven T et al (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856–860. doi: 10.1038/39885 CrossRefPubMedGoogle Scholar
  2. Andrade MA, Bork P (1995) HEAT repeats in the Huntington’s disease protein. Nat Genet 11:115–116. doi: 10.1038/ng1095-115 CrossRefPubMedGoogle Scholar
  3. Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4:398–403. doi: 10.1038/ng0893-398 CrossRefPubMedGoogle Scholar
  4. Arrasate M, Mitra S, Schweitzer ES et al (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810. doi: 10.1038/nature02998 CrossRefPubMedGoogle Scholar
  5. Bañez-Coronel M, Porta S, Kagerbauer B et al (2012) A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8:e1002481. doi: 10.1371/journal.pgen.1002481 CrossRefPubMedCentralPubMedGoogle Scholar
  6. Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24:4250–4258. doi: 10.1523/JNEUROSCI.3920-03.2004 CrossRefPubMedGoogle Scholar
  7. Baxendale S, Abdulla S, Elgar G et al (1995) Comparative sequence analysis of the human and pufferfish Huntington’s disease genes. Nat Genet 10:67–76. doi: 10.1038/ng0595-67 CrossRefPubMedGoogle Scholar
  8. Bemelmans AP, Horellou P, Pradier L et al (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10:2987–2997. doi: 10.1089/10430349950016393 CrossRefPubMedGoogle Scholar
  9. Benchoua A, Trioulier Y, Zala D et al (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652–1663. doi: 10.1091/mbc.E05-07-0607 CrossRefPubMedCentralPubMedGoogle Scholar
  10. Boutell JM, Thomas P, Neal JW et al (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington’s disease gene product, huntingtin. Hum Mol Genet 8:1647–1655CrossRefPubMedGoogle Scholar
  11. Canals JM, Pineda JR, Torres-Peraza JF et al (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci 24:7727–7739. doi: 10.1523/JNEUROSCI.1197-04.2004 CrossRefPubMedGoogle Scholar
  12. Chang DTW, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22:388–400. doi: 10.1016/j.nbd.2005.12.007 CrossRefPubMedGoogle Scholar
  13. Chattopadhyay B, Baksi K, Mukhopadhyay S, Bhattacharyya NP (2005) Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 374:81–86. doi: 10.1016/j.neulet.2004.10.018 CrossRefPubMedGoogle Scholar
  14. Chung DW, Rudnicki DD, Yu L, Margolis RL (2011) A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet 20:3467–3477. doi: 10.1093/hmg/ddr263 CrossRefPubMedCentralPubMedGoogle Scholar
  15. Cowan CM, Fan MMY, Fan J et al (2008) Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 28:12725–12735. doi: 10.1523/JNEUROSCI.4619-08.2008 CrossRefPubMedGoogle Scholar
  16. Craufurd D, Snowden JS (2002) Neuropsychological and neuropsychiatric aspects of Huntington’s disease. In: Harper P, Bates G, Jones L (eds) Huntington’s disease, 3rd edn. Oxford University Press, Oxford, pp 62–94Google Scholar
  17. Cui L, Jeong H, Borovecki F et al (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59–69. doi: 10.1016/j.cell.2006.09.015 CrossRefPubMedGoogle Scholar
  18. Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548CrossRefPubMedGoogle Scholar
  19. Desplats PA, Kass KE, Gilmartin T et al (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743–757. doi: 10.1111/j.1471-4159.2005.03588.x CrossRefPubMedGoogle Scholar
  20. Djoussé L, Knowlton B, Hayden MR et al (2004) Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 5:109–114. doi: 10.1007/s10048-004-0175-2 CrossRefPubMedCentralPubMedGoogle Scholar
  21. Dunah AW, Jeong H, Griffin A et al (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238–2243. doi: 10.1126/science.1072613 CrossRefPubMedGoogle Scholar
  22. Duyao MP, Auerbach AB, Ryan A et al (1995) Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269:407–410CrossRefPubMedGoogle Scholar
  23. Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17:475–492. doi: 10.1177/1073858410390378 CrossRefPubMedCentralPubMedGoogle Scholar
  24. Feng Z, Jin S, Zupnick A et al (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25:1–7. doi: 10.1038/sj.onc.1209021 CrossRefPubMedGoogle Scholar
  25. Fernandes HB, Baimbridge KG, Church J et al (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27:13614–13623. doi: 10.1523/JNEUROSCI.3455-07.2007 CrossRefPubMedGoogle Scholar
  26. Fiszer A, Krzyzosiak WJ (2013) RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J Mol Med 91:683–691. doi: 10.1007/s00109-013-1016-2 CrossRefPubMedCentralPubMedGoogle Scholar
  27. Gafni J, Ellerby LM (2002) Calpain activation in Huntington's disease. J Neurosci 22:4842–4849PubMedGoogle Scholar
  28. Gafni J, Hermel E, Young JE et al (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279:20211–20220. doi: 10.1074/jbc.M401267200 CrossRefPubMedGoogle Scholar
  29. Gauthier LR, Charrin BC, Borrell-Pagès M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138. doi: 10.1016/j.cell.2004.06.018 CrossRefPubMedGoogle Scholar
  30. Gissi C, Pesole G, Cattaneo E, Tartari M (2006) Huntingtin gene evolution in Chordata and its peculiar features in the ascidian Ciona genus. BMC Genomics 7:288. doi: 10.1186/1471-2164-7-288 CrossRefPubMedCentralPubMedGoogle Scholar
  31. Gladding CM, Sepers MD, Xu J et al (2012) Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum Mol Genet 21:3739–3752. doi: 10.1093/hmg/dds154 CrossRefPubMedCentralPubMedGoogle Scholar
  32. Goldberg YP, Nicholson DW, Rasper DM et al (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13:442–449. doi: 10.1038/ng0896-442 CrossRefPubMedGoogle Scholar
  33. Gonitel R, Moffitt H, Sathasivam K et al (2008) DNA instability in postmitotic neurons. Proc Natl Acad Sci USA 105:3467–3472. doi: 10.1073/pnas.0800048105 CrossRefPubMedCentralPubMedGoogle Scholar
  34. Graham RK, Pouladi MA, Joshi P et al (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29:2193–2204. doi: 10.1523/JNEUROSCI.5473-08.2009 CrossRefPubMedCentralPubMedGoogle Scholar
  35. Gu M, Gash MT, Mann VM et al (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385–389. doi: 10.1002/ana.410390317 CrossRefPubMedGoogle Scholar
  36. Hedreen JC, Peyser CE, Folstein SE, Ross CA (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 133:257–261CrossRefPubMedGoogle Scholar
  37. Holzmann C, Schmidt T, Thiel G et al (2001) Functional characterization of the human Huntington's disease gene promoter. Brain Res Mol Brain Res 92:85–97CrossRefPubMedGoogle Scholar
  38. Huang K, Yanai A, Kang R et al (2004) Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron 44:977–986. doi: 10.1016/j.neuron.2004.11.027 CrossRefPubMedGoogle Scholar
  39. Humbert S, Bryson EA, Cordelières FP et al (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2:831–837CrossRefPubMedGoogle Scholar
  40. Huntington G (1872) On Chorea. Med Surg Rep 26:317–321Google Scholar
  41. Imarisio S, Carmichael J, Korolchuk V et al (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412:191–209. doi: 10.1042/BJ20071619 CrossRefPubMedGoogle Scholar
  42. Jasinska A, Michlewski G, de Mezer M et al (2003) Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res 31:5463–5468CrossRefPubMedCentralPubMedGoogle Scholar
  43. Johnson R, Zuccato C, Belyaev ND et al (2008) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 29:438–445. doi: 10.1016/j.nbd.2007.11.001 CrossRefPubMedGoogle Scholar
  44. Kalchman MA, Graham RK, Xia G et al (1996) Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 271:19385–19394CrossRefPubMedGoogle Scholar
  45. Lawlor KT, O’Keefe LV, Samaraweera SE et al (2011) Double-stranded RNA is pathogenic in Drosophila models of expanded repeat neurodegenerative diseases. Hum Mol Genet 20:3757–3768. doi: 10.1093/hmg/ddr292 CrossRefPubMedGoogle Scholar
  46. Leavitt BR, Guttman JA, Hodgson JG et al (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68:313–324. doi: 10.1086/318207 CrossRefPubMedCentralPubMedGoogle Scholar
  47. Leavitt BR, Van Raamsdonk JM, Shehadeh J et al (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96:1121–1129. doi: 10.1111/j.1471-4159.2005.03605.x CrossRefPubMedGoogle Scholar
  48. Li L, Fan M, Icton CD et al (2003) Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 24:1113–1121CrossRefPubMedGoogle Scholar
  49. Li L, Murphy TH, Hayden MR, Raymond LA (2004) Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol 92:2738–2746. doi: 10.1152/jn.00308.2004 CrossRefPubMedGoogle Scholar
  50. Lin B, Rommens JM et al (1993) Differential 3′ polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Hum Mol Genet 2(10):1541–1545CrossRefPubMedGoogle Scholar
  51. Lin B, Nasir J, Kalchman MA et al (1995) Structural analysis of the 5′ region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics 25:707–715CrossRefPubMedGoogle Scholar
  52. Liot G, Zala D, Pla P et al (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33:6298–6309. doi: 10.1523/JNEUROSCI.2033-12.2013 CrossRefPubMedGoogle Scholar
  53. Luo S, Vacher C, Davies JE, Rubinsztein DC (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169:647–656. doi: 10.1083/jcb.200412071 CrossRefPubMedCentralPubMedGoogle Scholar
  54. MacDonald ME, Vonsattel JP, Shrinidhi J et al (1999) Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease. Neurology 53:1330–1332CrossRefPubMedGoogle Scholar
  55. Mahant N, McCusker EA, Byth K et al (2003) Huntington’s disease: clinical correlates of disability and progression. Neurology 61:1085–1092CrossRefPubMedGoogle Scholar
  56. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517–519CrossRefPubMedGoogle Scholar
  57. Mende-Mueller LM, Toneff T, Hwang SR et al (2001) Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington’s disease striatum. J Neurosci 21:1830–1837PubMedGoogle Scholar
  58. Milakovic T, Quintanilla RA, Johnson GVW (2006) Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 281:34785–34795. doi: 10.1074/jbc.M603845200 CrossRefPubMedGoogle Scholar
  59. Mizuno K, Carnahan J, Nawa H (1994) Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 165:243–256. doi: 10.1006/dbio.1994.1250 CrossRefPubMedGoogle Scholar
  60. Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington’s disease. J Neurochem 76:166–172CrossRefPubMedGoogle Scholar
  61. Myers RH, Leavitt J, Farrer LA et al (1989) Homozygote for Huntington disease. Am J Hum Genet 45:615–618PubMedCentralPubMedGoogle Scholar
  62. Mykowska A, Sobczak K, Wojciechowska M et al (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res 39:8938–8951. doi: 10.1093/nar/gkr608 CrossRefPubMedCentralPubMedGoogle Scholar
  63. Nasir J, Floresco SB, O’Kusky JR et al (1995) Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811–823CrossRefPubMedGoogle Scholar
  64. Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT (2003) In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington’s disease. Arch Biochem Biophys 410:1–6CrossRefPubMedGoogle Scholar
  65. Pineda JR, Canals JM, Bosch M et al (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington’s disease. J Neurochem 93:1057–1068. doi: 10.1111/j.1471-4159.2005.03047.x CrossRefPubMedGoogle Scholar
  66. Pringsheim T, Wiltshire K, Day L et al (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 27:1083–1091. doi: 10.1002/mds.25075 CrossRefPubMedGoogle Scholar
  67. Reiner A, Dragatsis I, Zeitlin S, Goldowitz D (2003) Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 28:259–276. doi: 10.1385/MN:28:3:259 CrossRefPubMedGoogle Scholar
  68. Rigamonti D, Bauer JH, De-Fraja C et al (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705–3713PubMedGoogle Scholar
  69. Rigamonti D, Sipione S, Goffredo D et al (2001) Huntingtin’s neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545–14548. doi: 10.1074/jbc.C100044200 CrossRefPubMedGoogle Scholar
  70. Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 110:2366–2370. doi: 10.1073/pnas.1221891110 CrossRefPubMedCentralPubMedGoogle Scholar
  71. Schwarcz R, Foster AC, French ED et al (1984) Excitotoxic models for neurodegenerative disorders. Life Sci 35:19–32CrossRefPubMedGoogle Scholar
  72. Sheng M, Kim MJ (2002) Postsynaptic signaling and plasticity mechanisms. Science 298:776–780. doi: 10.1126/science.1075333 CrossRefPubMedGoogle Scholar
  73. Shimohata T, Nakajima T, Yamada M et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26:29–36. doi: 10.1038/79139 CrossRefPubMedGoogle Scholar
  74. Smith R, Petersén A, Bates GP et al (2005) Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiol Dis 20:673–684. doi: 10.1016/j.nbd.2005.05.008 CrossRefPubMedGoogle Scholar
  75. Sobczak K, de Mezer M, Michlewski G et al (2003) RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res 31:5469–5482CrossRefPubMedCentralPubMedGoogle Scholar
  76. Spargo E, Everall IP, Lantos PL (1993) Neuronal loss in the hippocampus in Huntington’s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatr 56:487–491CrossRefPubMedCentralPubMedGoogle Scholar
  77. Steffan JS, Kazantsev A, Spasic-Boskovic O et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97:6763–6768. doi: 10.1073/pnas.100110097 CrossRefPubMedCentralPubMedGoogle Scholar
  78. Steffan JS, Agrawal N, Pallos J et al (2004) SUMO modification of Huntingtin and Huntington’s disease pathology. Science 304:100–104. doi: 10.1126/science.1092194 CrossRefPubMedGoogle Scholar
  79. Takano H, Gusella JF (2002) The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci 3:15CrossRefPubMedCentralPubMedGoogle Scholar
  80. Tanaka K, Shouguchi-Miyata J, Miyamoto N, Ikeda J-E (2004) Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington’s disease gene. J Biol Chem 279:7275–7286. doi: 10.1074/jbc.M310726200 CrossRefPubMedGoogle Scholar
  81. Tartari M, Gissi C, Sardo Lo V et al (2008) Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 25:330–338. doi: 10.1093/molbev/msm258 CrossRefPubMedGoogle Scholar
  82. The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983Google Scholar
  83. Van Raamsdonk JM, Pearson J, Rogers DA et al (2005a) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379–1392. doi: 10.1093/hmg/ddi147 CrossRefPubMedGoogle Scholar
  84. Van Raamsdonk JM, Pearson J, Slow EJ et al (2005b) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 25:4169–4180. doi: 10.1523/JNEUROSCI.0590-05.2005 CrossRefPubMedGoogle Scholar
  85. Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26:512–520. doi: 10.1016/j.nbd.2007.01.006 CrossRefPubMedGoogle Scholar
  86. Ventimiglia R, Mather PE, Jones BE, Lindsay RM (1995) The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 7:213–222CrossRefPubMedGoogle Scholar
  87. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384CrossRefPubMedGoogle Scholar
  88. Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18:737–752. doi: 10.1093/hmg/ddn404 CrossRefPubMedCentralPubMedGoogle Scholar
  89. Wang R, Luo Y, Ly PTT et al (2012) Sp1 regulates human huntingtin gene expression. J Mol Neurosci. doi: 10.1007/s12031-012-9739-z PubMedCentralGoogle Scholar
  90. Warby SC, Chan EY, Metzler M et al (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14:1569–1577. doi: 10.1093/hmg/ddi165 CrossRefPubMedGoogle Scholar
  91. Warby SC, Montpetit A, Hayden AR et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84:351–366. doi: 10.1016/j.ajhg.2009.02.003 CrossRefPubMedCentralPubMedGoogle Scholar
  92. Wellington CL, Ellerby LM, Hackam AS et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273:9158–9167CrossRefPubMedGoogle Scholar
  93. Wexler NS, Young AB, Tanzi RE et al (1987) Homozygotes for Huntington’s disease. Nature 326:194–197. doi: 10.1038/326194a0 CrossRefPubMedGoogle Scholar
  94. White JK, Auerbach W, Duyao MP et al (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17:404–410. doi: 10.1038/ng1297-404 CrossRefPubMedGoogle Scholar
  95. Xia J, Lee DH, Taylor J et al (2003) Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 12:1393–1403CrossRefPubMedGoogle Scholar
  96. Young FB, Butland SL, Sanders SS et al (2012) Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Prog Neurobiol 97:220–238. doi: 10.1016/j.pneurobio.2011.11.002 CrossRefPubMedGoogle Scholar
  97. Yu Z, Teng X, Bonini NM (2011) Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model for myotonic dystrophy. PLoS Genet 7:e1001340. doi: 10.1371/journal.pgen.1001340 CrossRefPubMedCentralPubMedGoogle Scholar
  98. Zeitlin S, Liu JP, Chapman DL et al (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11:155–163. doi: 10.1038/ng1095-155 CrossRefPubMedGoogle Scholar
  99. Zhang Y, Li M, Drozda M et al (2003) Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 87:101–106CrossRefPubMedGoogle Scholar
  100. Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498. doi: 10.1126/science.1059581 CrossRefPubMedGoogle Scholar
  101. Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76–83. doi: 10.1038/ng1219 CrossRefPubMedGoogle Scholar
  102. Zuccato C, Belyaev N, Conforti P et al (2007) Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington’s disease. J Neurosci 27:6972–6983. doi: 10.1523/JNEUROSCI.4278-06.2007 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research InstituteUniversity of British ColumbiaVancouverCanada

Personalised recommendations